Basilea Pharmaceutica AG
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Veitch
- Full Time Employees
- 189
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hegenheimermattweg 167b Allschwil BL Switzerland 4123
- IPO Date
- Mar 25, 2004
- Website
- basilea.com
- Similar Companies
- Business
- Basilea Pharmaceutica AG (BSLN.SW) is a Swiss biopharmaceutical company focused on discovering, developing, and commercializing innovative drugs for severe bacterial and fungal infections. The company offers a portfolio of approved products including Cresemba (isavuconazole), an azole antifungal agent for invasive aspergillosis and mucormycosis; Zevtera (ceftobiprole), a broad-spectrum cephalosporin antibiotic for community- and hospital-acquired pneumonia, acute bacterial skin infections, and Staphylococcus aureus bacteremia; and Deucravacitinib (Sotyktu), a TYK2 inhibitor licensed for moderate-to-severe plaque psoriasis in certain markets. Its pipeline includes lisocabtagene maraleucel (liso-cel), a CD19-directed CAR-T cell therapy partnered with Janssen Biotech for hematologic malignancies, and preclinical candidates targeting gram-negative bacteria. Basilea operates primarily in the anti-infectives segment, serving hospitals, infectious disease specialists, and healthcare systems with a focus on hospital-based therapies; it conducts research and commercialization across Europe, North America, and Asia-Pacific. Founded in 2000 and headquartered in Basel, Switzerland, the company has no major subsidiaries but maintains strategic alliances with global partners for development and distribution. In late 2024, Basilea completed the acquisition of innovative anti-infective assets from a major pharmaceutical firm, bolstering its pipeline amid rising antimicrobial resistance; earlier in 2025, it announced a landmark funding round exceeding CHF 150 million to support Phase 3 trials for Zevtera expansions and new antifungal launches; additionally, the company entered a co-development partnership with a leading Asian biotech for next-generation beta-lactamase inhibitors targeting multidrug-resistant pathogens.
Company News
Basilea gibt Präsentation neuer Daten zu Fosmanogepix, Isavuconazol und Ceftobiprol auf der IDWeek 2026 bekannt
Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026
Basilea Pharmaceutica AG (BPMUF) Q2 2026 Earnings Call Transcript
Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Basilea erhält weitere USD 13 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
Basilea erhält zusätzliche USD 6 Mio. von CARB-X für die klinische Entwicklung des Antibiotikums BAL2420
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Basilea startet erste klinische Studie am Menschen für neuartiges Antibiotikum BAL2420
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript
Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Basilea provides portfolio update and outlook
Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections
Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI